Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
Go back to Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer| VERASTEM SHS (NASDAQ: VSTM) | Delayed: 6.16 +0.27 (4.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.89 | 52 Week High | $2.43 | |||
| Open | $5.87 | 52 Week Low | $1.05 | |||
| Day High | $6.31 | P/E | N/A | |||
| Day Low | $5.75 | EPS | $-1.79 | |||
| Volume | 1,691,552 | |||||
